Center for Biophysics and Quantitative Biology Master Calendar

Back to Listing

How Pets are Accelerating Cancer Treatment in Humans

Event Type
Carl R. Woese Institute for Genomic Biology and Cancer Center at Illinois
wifi event
Apr 28, 2021   12:00 pm  
Dr. Paul Hergenrother, Cancer Center at Illinois Deputy Director, Professor of Chemistry, and Affiliate in Biochemistry at the University of Illinois
Originating Calendar
Bioengineering calendar

Join Paul J. Hergenrother, PhD, Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry, in an exclusive conversation about how our pets are helping treat cancer in humans. Dr. Hergenrother will highlight drug discovery efforts, including new breakthrough treatments currently in phase 1 of human trials.

About Dr. Paul Hergenrother
Prof. Hergenrother is a Professor of Chemistry, and Affiliate in Biochemistry at the University of Illinois, and the co-founder and Chief Scientific Officer of Vanquish Oncology. Professor Hergenrother is the theme leader of the Carl R. Woese Institute for Genomic Biology’s “Anticancer Discovery from Pets to People,” and is the Director of the NIH Chemistry-Biology Interface Training Grant. Additionally, Hergenrother serves as the Cancer Center at Illinois’ Deputy Director. The Hergenrother laboratory seeks to use small molecules to identify and validate novel targets for the treatment of intractable cancers.

About Anticancer Discovery from Pets to People
The “Anticancer Discovery from Pets to People” (ACCP) theme is taking a novel approach to the elucidation of new anticancer targets and the discovery of anticancer drugs, enabled by comparative tumor oncology and genomics through the inclusion of companion animals (dogs and cats) with cancer. The ACPP theme leverages combinations of resources that are unique to the University of Illinois, including strengths in drug discovery, veterinary medicine, and computational comparative oncology. These efforts have led to breakthrough discoveries in the development of novel cancer drugs: compounds that hit new targets, have a higher likelihood of success when advanced into human clinical trials, and can be identified and developed at a fraction of the cost of conventional methods.

link for robots only